<div id="readability-page-1"><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Ultragenyx Pharmaceutical, Praxis Precision Medicines, AbbVie,  and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies primarily engaged in researching, developing, manufacturing, and marketing prescription drugs and therapies. For investors, these stocks offer exposure to the healthcare and drug-development sector but carry specific risks and rewards — they can be volatile around clinical trial results, regulatory approvals, patents and pricing decisions, yet may provide significant growth potential or defensive demand depending on the company and product pipeline. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Sector Rotation: 2 Smart Money Moves for 2026</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Read Our Latest Research Report on NVO</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><p>Read Our Latest Research Report on PFE</p><h2>Ultragenyx Pharmaceutical (RARE)</h2><p>Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.</p><p>Read Our Latest Research Report on RARE</p><h2>Praxis Precision Medicines (PRAX)</h2><p>Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p><p>Read Our Latest Research Report on PRAX</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Bristol Myers Squibb (BMY)</h2><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><p>Read Our Latest Research Report on BMY</p><h2>Featured Articles</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>Broadcom's Insider Selling: A Big Red Flag, or Business as Usual?</li><li>Verizon: Out of the Doghouse and Into Your Dividend Portfolio</li><li>3 Picks-and-Shovels Ways to Invest in AI Without Betting on Chipmakers</li><li>Gold and Silver Are on Fire—These Canadian Miners Ride the Wave</li><li>Qualcomm Shares Are Back Near Their 2021 Price—Should Investors Be Worried or Excited?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRAX

ABBV

<p>Eli Lilly, Novo Nordisk, Pfizer, Ultragenyx, Praxis Precision Medicines, AbbVie, and Bristol Myers Squibb are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are engaged in drug development and marketing, offering potential growth but also facing volatility due to clinical trials and regulatory approvals. They have shown high trading volumes recently, indicating investor interest in the healthcare sector.</p>

Top Pharmaceutical Stocks To Research - December 29th